These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16781793)

  • 21. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance.
    Jin J; Yu Y; Yu H; Wang C; Zhang X
    Diabetes Res Clin Pract; 2006 Dec; 74(3):233-41. PubMed ID: 16764964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.
    Voytovich MH; Simonsen C; Jenssen T; Hjelmesaeth J; Asberg A; Hartmann A
    Nephrol Dial Transplant; 2005 Feb; 20(2):413-8. PubMed ID: 15615809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults.
    Hernández-Corona DM; Martínez-Abundis E; González-Ortiz M
    J Med Food; 2014 Jul; 17(7):830-2. PubMed ID: 24611906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study.
    Cali AM; Pierpont BM; Taksali SE; Allen K; Shaw MM; Savoye M; Caprio S
    Obesity (Silver Spring); 2011 Jan; 19(1):94-9. PubMed ID: 20467418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).
    Nijpels G; Boorsma W; Dekker JM; Kostense PJ; Bouter LM; Heine RJ
    Diabetes Metab Res Rev; 2008; 24(8):611-6. PubMed ID: 18756586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
    Yao-Borengasser A; Varma V; Bodles AM; Rasouli N; Phanavanh B; Lee MJ; Starks T; Kern LM; Spencer HJ; Rashidi AA; McGehee RE; Fried SK; Kern PA
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2590-7. PubMed ID: 17595259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
    Füllert S; Schneider F; Haak E; Rau H; Badenhoop K; Lübben G; Usadel KH; Konrad T
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5503-6. PubMed ID: 12466345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of
    Gaytán Martínez LA; Sánchez-Ruiz LA; Zuñiga LY; González-Ortiz M; Martínez-Abundis E
    J Med Food; 2021 Jan; 24(1):28-32. PubMed ID: 32460589
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.